Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for BMF-219 in Type 1 Diabetes BMF-219 是一种新型共价脑膜素抑制剂,旨在再生产生胰岛素的 β 细胞,旨在治愈 1 型糖尿病 美国食品药品管理局已批准启动 COVALENT-112,这是一项针对成人 1 型糖尿病 (T1D) 的 BMF-219 ...
"We are very excited to announce the initial response data from the first two type 1 diabetes patients enrolled in the COVALENT-112 study. Both patients showed improvement in measures of beta-cell function after only 4 weeks of dosing with BMF-219. We are rapidly gathering significant proof po...
BMF-219是Biomea的新型研究性共价Menin抑制剂。在公布治疗II型糖尿病药物的临床数据后，Biomea Fusion股价截至发稿上涨115.52%，达到32.35美元/股。其股价在过去一年内上涨超600%。Ⅱ型糖尿病（diabetes mellitus type Ⅱ，T2DM），旧称非胰岛素依赖型糖尿病（noninsulin-dependent diabetes mellitus，NIDDM）或成人发...
患者将按1:1:1的比例接受为期12周的100mg或200mg BMF-219或安慰剂治疗,随后进行为期40周的访视。 原文链接: https://www.biospace.com/article/releases/biomea-fusion-announces-fda-clearance-of-investigational-new-drug-ind-application-for-bmf-219-in-type-1-diabetes-/ 市监总...
Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA) today announced that it will present new clinical data from the ongoing Phase II portion of its COVALENT-111 trial, which is evaluating BMF-219 as a potential treatmen...
BMF-219 is a covalent inhibitor that suppresses the menin protein, which is involved in oncogenic signaling in genetically defined leukemias and diabetes. Preclinically, BMF-219 has shown robust downregulation of leukemogenic genes and menin in acute leukemia cell lines. Additionally, BMF-219 has...
the clinical and therapeutic potential of our product candidates and development programs, including BMF-219, the potential of BMF-219 as a treatment for various types of cancer and diabetes, our research, development and regulatory plans, including our pursuit of BMF-219 in KRAS solid tumors, an...
901-P: COVALENT 112—A Clinical Trial Assessing BMF-219, an Oral Covalent Menin Inhibitor in Type 1 Diabetesdoi:10.2337/db24-901-PBackground and Aims: Inhibition of menin, a scaffold protein, results in beta cell proliferation and enhanced insulin secretion in T1D. BMF-219, an oral ...
[1] Biomea Fusion Announces Positive Data from Initial Cohorts of Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes; 100 mg Cohort 3 Demonstrated an 89% Response Rate and 1% Median Reduction in HbA1c at Day 28. Retrieved March 28, 2023, from https://ww...